Practical guides · Practical guide

CSA workshops for pharma: defining scope and making test decisions

Before booking a CSA workshop to improve documentation, establish the regulatory scope. FDA CSA guidance concerns production and quality management system software in the medical device sector. It grants no blanket permission for human medicines manufacturing. A suitable workshop explains the distinction and then applies it to the actual decisions your team needs to make.

Table of contents

At a glance

What should a CSA workshop deliver for a pharmaceutical team?

A CSA workshop should place the project in its regulatory context and explain the current FDA guidance. Distinguish medical device scope from requirements applicable to the team’s GMP use. Use an actual case to assess risk, choose suitable testing and decide what evidence is sufficient. Document decisions and open questions. Blanket promises to eliminate CSV, testing or traceable records are not a sound basis.

  • The FDA final guidance of 3 February 2026 replaces the version of 24 September 2025.
  • Your immediate subject matter is software for manufacturing and Quality Management System (QMS) of medical devices.
  • Risk-based thinking does not constitute exemption from applicable GMP requirements.
  • The outcomes of the workshop should enable traceable decisions based on actual case examples.

What requirements apply to participants?

Capture the product area, processes, and considered software. A company may have different activities; the same internal designation "Pharma" does not fully address regulatory questions. For a human pharmaceutical GMP system, the applicable requirements remain decisive.

Present the FDA CSA guidance with its title, date and scope. The final guidance of 3 February 2026 supersedes the September 2025 version. Read it in the context of the medical device Quality Management System Regulation, 21 CFR Part 820. Establish this scope even in a pharmaceutical workshop and correct references that still present an earlier draft as current.

Sources: [1] [2] [3]

Further reading:

Collect specific areas for improvement prior to the workshop

Query which activities currently provide little assurance. Are similar tests repeatedly performed? Are expected results unclear? Does documentation take longer because requirements are only clarified during execution? These causes require different improvements.

A general objective of "fewer tests" presupposes the existence of a solution. A more appropriate question is: how can the required evidence be generated with appropriate effort and sufficient credibility? This approach also ensures that cases remain visible in which a previously superficial test must be deepened.

Sources: [4] [5]

A case leads from risk consideration to evidence of compliance

In the workshop, initially separate the medical device scope of the FDA Guidance from your specific GMP application. The matrix identifies which questions the team can address in a representative case scenario; it is not a prescribed CSA template.

The team should be able to justify its conclusions. A completed form without clear rationale provides limited value. Where information is missing, an open question should be retained instead of assigning an appropriate risk category.

A case leads from risk consideration to evidence of compliance
StepQuestion to the teamViable result
Use What task does the software support? Specific Purpose and System Boundaries
Error What could go wrong for this purpose? Relevant types of errors and their consequences
Control What existing measures are in place to counteract this? Justified technical and organizational controls
Verification What insight is still missing? Appropriate test method with expected reliability
Evidence What must later be traceable? Appropriate documentation of status, actions taken, and results
Operation What triggers a re-evaluation? Clear process for changes and deviations

Sources: [2] [4] [5]

Select sample batches based on stated potency rather than label claims

The FDA Guidance outlines various appropriate testing approaches within its applicable scope. Terms such as script-based or less script-bound do not substitute for the rationale explaining why a test provides the required assurance. Similarly, an exploratory approach must include sufficient clarity regarding its objective and the actual insights gained.

For your GMP system, in addition to verifying whether the selected approach meets applicable requirements and internal procedures, it must be established that a standard form does not automatically enhance validation evidence. Conversely, an additional detailed specification may be unnecessary if its information is already appropriate and clearly documented.

Sources: [2] [5]

Further reading:

Utilize supplier documentation and existing testing records appropriately

A workshop can evaluate which supplier certifications are actually applicable. Compare considered versions, features, environment, and results against actual usage. Not every existing technical validation addresses the specific technical requirements; not every internal question necessitates a full revalidation.

The rationale for any additional requirements should be clearly justified. A general assertion that an unknown test package is sufficient is equally inappropriate, as is a blanket rejection of all evidence. Responsibilities and quality requirements between supplier and operator must remain explicitly defined.

Sources: [5] [6]

Planning example: The valid work instruction at the manufacturing site

For this exercise, it is explicitly assumed that the company is a medical device manufacturer operating under FDA regulations. Its Quality Management System (QMS) software provides work instructions at a designated manufacturing location. A configuration change involves the assignment of the current valid version. The group identifies which incorrect version assignment could potentially impact product quality, evaluates existing validation evidence, and outlines how the specific change is appropriately assessed.

Are the intended use, mechanism of action, and existing evidence clearly defined can a targeted validation for the specified association and its boundaries be justified? If it remains unclear which additional positions or roles are involved, the group must first establish a more precise scope. The review decision shall be justified on a risk-based basis. The example scenario thus presents a thought exercise for the workshop, not a predefined number of test scripts to be eliminated.

Sources: [1] [2]

Changes to the procedure for deriving batches from the workshop

A workshop can generate valuable improvement ideas, but it does not automatically alter the operational quality procedures. First, describe the proposed changes, expected benefits, and relevant tasks involved. Assess which roles, templates, and training programs would need to be adjusted, and identify which requirements must still be validated.

Test a suitable limited change and evaluate its outcome. The benefit should be clearly demonstrated through understandable evidence and minimized unnecessary repetition. A simple reduction in page count may, in contrast, result in a loss of essential information. The key factor is sufficient clarity and relevance to the intended purpose.

Sources: [5] [7]

What a suitable trainer should be able to explain

An appropriate trainer must be able to explain the scope, current status, and limitations of the guidance. They should be able to review your cases and identify genuine open questions. Generic promises of fixed percentage cost savings or general document reduction are not a reliable foundation.

Align the outcomes with a justified case assessment, specific procedural recommendations, and a coordinated next inspection step. Clarify which activities constitute pure learning simulations and which should be transitioned into actual project or change processes. This transforms a single keyword into a valuable contribution.

  • Clarify current guidance and actual scope of applicability.
  • Address the need for specific tasks rather than general cost-cutting objectives.
  • Consequences, controls, and lack of awareness are interconnected.
  • Verify the credibility of existing evidence.
  • Investigate and validate process changes and transfer them.

Sources: [1] [2] [6]

Project experience and collaboration

Use a CSA workshop to evaluate a specific testing approach

First establish which guidance applies to the intended use. The team then works through a case. What failures matter, how could you detect them and which record would explain the test? More than one approach may be justified. Your responsible staff decide which approach to adopt in your procedures, based on the applicable requirements and actual use.

Frequent Questions about the CSA Workshop

Does CSA replace computerized system validation in pharma completely?

No. The FDA-CSA Guidance pertains to production and quality management software in the medical device sector. For use in human medicinal product manufacturing, the applicable GMP requirements set forth in the guidance are decisive. Methodological recommendations from CSA may be discussed, but must be justified and contextualized within the specific domain of operation.

Sources: [2] [5]

Which version should a current workshop use?

On the verification date, the FDA final guidance of February 3, 2026 is a major up-to-date reference. It replaces the version of September 24, 2025. The official FDA page and the linked document should be checked for changes prior to a new project.

Sources: [1] [2]

Does reduced script-bound testing imply that documentation is no longer required?

No. The approach must enable a sufficient and traceable justification for its intended purpose. The objective, actual status, and results must not remain unclear. The appropriate evidence is to be determined in the specific regulatory area and procedure.

Sources: [2] [5]

Can we promise a fixed cost saving through CSA?

Without a clear starting point and reliable measurement, a general percentage figure is inappropriate. Some initiatives may reduce unnecessary repetition; others require first clearer requirements or additional supporting evidence. Agree on verifiable improvement objectives instead of generic promises.

Can we bring our own project cases?

This is often appropriate when the scope and information align with the learning objective. Confidential content should be handled appropriately. Results from learning activities must be distinguished from officially approved project documentation and should be reviewed for suitability when reused.

What should specifically be available following the workshop?

Clear evaluations of handled cases, limited procedural suggestions, and open questions raised with responsible parties are helpful. A large presentation set alone does not adequately address the specific application. The next steps should align with your quality and project procedures.

Sources and review date

Primary source date: 17 October 2026. The current FDA reference is the Final Guidance issued on 3 February 2026 for production and QMS software in the medical device sector. Its applicability to human medicinal product GMP is explicitly not assumed. Matrices and workshop example for instruction assignment are standalone didactic aids. Regulatory requirements and methodological improvements are separately justified.

  1. FDA: Computer Software Assurance for Production and Quality Management System Software, Final Guidance, February 2026Covers medical device production and quality management systems. Its scope does not automatically extend to every pharmaceutical GMP application.
  2. FDA: Computer Software Assurance, complete Final Guidance dated February 3, 2026Scope and risk-based Assurance, no blanket percentage or document reduction savings.
  3. European Commission: EudraLex Volume 4 – current publication inventoryDate: 17.10.2026; Separate human medicinal products from veterinary medicinal products governed by the amended veterinary medicinal product regulations effective from 16.07.2026.
  4. ICH Q9(R1): Quality Risk Management, official text from the European CommissionRisk-driven decisions, appropriate formalities, and handling of subjectivity; own matrices are implementation proposals.
  5. European Commission: EU GMP Annex 11, Computerised Systems, January 2011 revisionHuman medicinal products – GMP; in particular, §§1–4, 7, 10–13, 16–17; specific application for each section.
  6. European Commission: EU GMP Chapter 7, Outsourced ActivitiesOutsourced GMP-related activities, suitability, responsibilities, agreements, and monitoring.
  7. European Commission: EU GMP Chapter 2, Personnel, effective from 16.02.2014Personal, role-specific training and assessment of practical effectiveness; official EudraLex entry with original chapter.

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Select a test that is difficult to justify today

Bring requirements, risk assessment, and existing evidence together for a limited case. From this, it can be clarified which statement is needed and how an appropriate workshop can contribute to a better decision.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →